BC Week In Review | Mar 8, 2010
Company News

AstraZeneca, Merck deal

AstraZeneca will exercise an option to acquire Merck's interest in four AstraZeneca drugs for $647 million. The four marketed products are Atacand candesartan cilexetil to treat hypertension and heart failure; Lexxel enalapril/felodipine ER and Plendil...
BC Week In Review | Mar 3, 2008
Company News

AstraZeneca, Merck & Co. Inc deal

AstraZeneca has an option to purchase Merck’s rights to those eight products in 2010 for about $650 million. If AstraZeneca exercises that option, the company will receive a second option to repurchase Merck’s rights to...
BC Extra | Feb 29, 2008
Company News

Merck, AstraZeneca shuffle JV

Merck (NYSE:MRK) will receive a net payment of about $2.6 billion this quarter from AstraZeneca (LSE:AZN; NYSE:AZN) under a restructuring of the companies' Astra Merck JV, which markets AstraZeneca's drugs in the U.S. Merck will...
Items per page:
1 - 3 of 3